Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to find if levels of a protein called AXL in tumor cells
relate to how tumors respond to cetuximab (CTX) combined with imatinib in participants with
head and neck cancer. This interventional study will occur in the time between diagnosis of
your cancer and surgery to remove your tumor or radiation or chemoradiation treatment of your
primary cancer.
Participants will undergo a research blood draw and a research biopsy as part of the
screening process, and will be in this research study for approximately 13 to 16 months.